CytRx Corp

Company Profile

CytRx Corp had its IPO on 1986-11-10 under the ticker symbol CYTR.

The company operates in the Healthcare sector and Biotechnology & Medical Research industry. CytRx Corp has a staff strength of 3 employees.

Stock update

Shares of CytRx Corp opened at $0.16 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $0.16 - $0.18, and closed at $0.18.

This is a +10.97% increase from the previous day's closing price.

A total volume of 7,653 shares were traded at the close of the day’s session.

In the last one week, shares of CytRx Corp have increased by +11.8%.

CytRx Corp's Key Ratios

CytRx Corp has a market cap of $4.14 million, indicating a price to book ratio of 3.7133 and a price to sales ratio of 34.4758.

In the last 12-months CytRx Corp’s revenue was $0 with a gross profit of $0 and an EBITDA of $-5947207. The EBITDA ratio measures CytRx Corp's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, CytRx Corp’s operating margin was 0% while its return on assets stood at -52% with a return of equity of -291.89%.

In Q3, CytRx Corp’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

CytRx Corp’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

0

Its diluted EPS in the last 12-months stands at $-0.355 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into CytRx Corp’s profitability.

CytRx Corp stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -0.176. Its price to sales ratio in the trailing 12-months stood at 34.4758.

CytRx Corp stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$3.38 million

Total Liabilities

$2.26 million

Operating Cash Flow

$0

Capital Expenditure

$0

Dividend Payout Ratio

0%

CytRx Corp ended 2024 with $3.38 million in total assets and $0 in total liabilities. Its intangible assets were valued at $3.38 million while shareholder equity stood at $1.04 million.

CytRx Corp ended 2024 with $0 in deferred long-term liabilities, $2.26 million in other current liabilities, in common stock, $-487824649.00 in retained earnings and $0 in goodwill. Its cash balance stood at $3.02 million and cash and short-term investments were $0. The company’s total short-term debt was $0 while long-term debt stood at $0.

CytRx Corp’s total current assets stands at $3.09 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0.00 compared to accounts payable of $903141.00 and inventory worth $0.

In 2024, CytRx Corp's operating cash flow was $0 while its capital expenditure stood at $0.

Comparatively, CytRx Corp paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$0.18

52-Week High

$0.22

52-Week Low

$0.05

Analyst Target Price

$

CytRx Corp stock is currently trading at $0.18 per share. It touched a 52-week high of $0.22 and a 52-week low of $0.22. Analysts tracking the stock have a 12-month average target price of $.

Its 50-day moving average was $0.16 and 200-day moving average was $0.17 The short ratio stood at 1.96 indicating a short percent outstanding of 0%.

Around 976.9% of the company’s stock are held by insiders while 935.6% are held by institutions.